Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 22, 2021

Thermo Fisher introduces new Covid-19 test for variant detection

The test can detect existing and emergent SARS-CoV-2 variants by using eight targets across three genomic regions of the virus.

Thermo Fisher Scientific has introduced its new Covid-19 test, TaqPath COVID-19 Fast PCR Combo Kit 2.0, growing its portfolio of tests for precise SARS-CoV-2 detection.

The CE-IVD-marked test is designed for identifying existing and emergent SARS-CoV-2 variants by using eight targets across three of the virus’s genomic regions.

This technique aids in delivering precise results even as the virus mutates, Thermo Fisher said.

The TaqPath test directly evaluates raw saliva with a two-hour turnaround time to aid in extensive and high-frequency testing.

Thermo Fisher genetic sciences senior medical director Manoj Gandhi said: “Covid-19 variants can be more transmissible and potentially impact efficacy of diagnostics, vaccines and therapies, threatening to reverse progress made in the past year.

“We are working to empower our customers to prepare for the next stage of the pandemic by future-proofing our test design against likely mutations and to provide continued confidence in their results.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

In March last year, the first generation TaqPath COVID-19 CE-IVD RT-PCR Kit and the TaqPath COVID-19 Combo Kit obtained both initial CE-IVD marking and Emergency Use Authorisation from the US Food and Drug Administration (FDA).

A single, high throughput test, the TaqPath COVID-19 CE-IVD RT-PCR kit can analyse up to 382 samples within two hours.

It is meant for the qualitative identification of SARS-CoV-2 nucleic acid in upper respiratory and bronchoalveolar lavage (BAL) samples from people suspected of having Covid-19.

The TaqPath COVID-19 Combo Kit can analyse up to 94 specimens within three hours.

This test is indicated to detect Covid-19 in samples obtained using nasopharyngeal swabs, nasopharyngeal aspirate and BAL from individuals who are at risk of contracting Covid-19 or have disease symptoms.

Earlier this month, Thermo Fisher Scientific launched its Ion AmpliSeq SARS-CoV-2 Insight Research Assay for early detection of emerging and known Covid-19 virus variants from samples with reduced lower viral loads.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy